LeMaitre Reports Q3 Sales Growth of 11% and Raises Full-Year EPS Outlook

What happened

LeMaitre reported third-quarter 2026 sales of $68.0 million, up 11% from a year earlier, and diluted earnings per share (EPS) of $0.65. It forecast full-year sales of $274.8 million to $276.8 million and EPS of $2.77 to $2.82.

Confirmed

Global impact / market context

Higher sales and the raised full-year outlook suggest stronger expected revenue and earnings. However, net income fell to $15.0 million from $17.4 million a year earlier, so investors may weigh growth against the decline in reported profit when assessing the business.

Analyst inference

Organic sales grew 12%, with 7% from pricing and 5% from unit growth, while the company also bought vascular assets for $19.2 million. Their sales are expected to move to LeMaitre’s channel over 18–24 months, linking future growth to execution.

Confirmed

What to watch

1. Watch whether quarterly sales and diluted EPS support the new annual forecast ranges of $274.8 million to $276.8 million and $2.77 to $2.82. Analyst inference
2. Track the 18–24-month transfer of acquired graft and instrument sales to LeMaitre’s channel; delays could postpone revenue from the $19.2 million asset purchase. Analyst inference
3. Compare future profit with sales growth, since third-quarter net income was $15.0 million versus $17.4 million a year earlier despite revenue rising to $68.0 million. Analyst inference

Evidence

• Original source link unavailable